These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 8390533)

  • 61. Cell- and stage-specific chromatin structure across the Complement receptor 2 (CR2/CD21) promoter coincide with CBF1 and C/EBP-beta binding in B cells.
    Cruickshank MN; Fenwick E; Karimi M; Abraham LJ; Ulgiati D
    Mol Immunol; 2009 Aug; 46(13):2613-22. PubMed ID: 19487031
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.
    Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE
    Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2.
    Martin DR; Yuryev A; Kalli KR; Fearon DT; Ahearn JM
    J Exp Med; 1991 Dec; 174(6):1299-311. PubMed ID: 1660522
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Binding of the Epstein-Barr virus to human platelets causes the release of transforming growth factor-beta.
    Ahmad A; Menezes J
    J Immunol; 1997 Oct; 159(8):3984-8. PubMed ID: 9378987
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2).
    Nemerow GR; Wolfert R; McNaughton ME; Cooper NR
    J Virol; 1985 Aug; 55(2):347-51. PubMed ID: 2410629
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The Epstein-Barr virus receptor on two nasopharyngeal carcinoma model cell lines.
    Takimoto T; Umeda R; Glaser R
    Acta Virol; 1989 Aug; 33(4):375-7. PubMed ID: 2574946
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The conserved domain CR2 of Epstein-Barr virus nuclear antigen leader protein is responsible not only for nuclear matrix association but also for nuclear localization.
    Yokoyama A; Kawaguchi Y; Kitabayashi I; Ohki M; Hirai K
    Virology; 2001 Jan; 279(2):401-13. PubMed ID: 11162796
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Epstein-Barr virus gene expression in oral hairy leukoplakia.
    Lau R; Middeldorp J; Farrell PJ
    Virology; 1993 Aug; 195(2):463-74. PubMed ID: 8393235
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2.
    Molina H; Kinoshita T; Inoue K; Carel JC; Holers VM
    J Immunol; 1990 Nov; 145(9):2974-83. PubMed ID: 2145366
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Detection of transcripts initiated from two viral promoters (Cp and Wp) in Epstein-Barr virus-infected nasopharyngeal carcinoma cells and biopsies.
    Chang Y; Sheen TS; Lu J; Huang YT; Chen JY; Yang CS; Tsai CH
    Lab Invest; 1998 Jun; 78(6):715-26. PubMed ID: 9645762
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cell phenotype-dependent splicing reflecting differential promoter usage for EBNA transcripts in EBV-carrying cells.
    Hu LF; Chen F; Altiok E; Winberg G; Klein G; Ernberg I
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():248-60. PubMed ID: 10895161
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
    Imai M; Ohta R; Varela JC; Song H; Tomlinson S
    Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Serum regulates the expression of complement receptor 2 on human B cell lines.
    Tolnay M; Tsokos GC
    Immunopharmacol Immunotoxicol; 2000 May; 22(2):205-19. PubMed ID: 10952027
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Increased expression of Epstein-Barr virus receptor on lymphoblastoid cell lines from subsets of patients with rheumatoid arthritis.
    Kahan A; Charriaut-Marlangue C; Kahan A; Barel M; Menkes CJ; Amor B; Frade R
    J Rheumatol; 1986 Dec; 13(6):1024-7. PubMed ID: 3494120
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immunolocalization of the lactotransferrin receptor on the human T lymphoblastic cell line Jurkat.
    Bi BY; Leveugle B; Liu JL; Collard A; Coppe P; Roche AC; Nillesse N; Capron M; Spik G; Mazurier J
    Eur J Cell Biol; 1994 Oct; 65(1):164-71. PubMed ID: 7889987
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2.
    Fingeroth JD; Weis JJ; Tedder TF; Strominger JL; Biro PA; Fearon DT
    Proc Natl Acad Sci U S A; 1984 Jul; 81(14):4510-4. PubMed ID: 6087328
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).
    Young KA; Chen XS; Holers VM; Hannan JP
    J Biol Chem; 2007 Dec; 282(50):36614-25. PubMed ID: 17925391
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Epstein-Barr virus (EBV) infection of murine L cells expressing recombinant human EBV/C3d receptor.
    Ahearn JM; Hayward SD; Hickey JC; Fearon DT
    Proc Natl Acad Sci U S A; 1988 Dec; 85(23):9307-11. PubMed ID: 2848261
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.
    Sarrias MR; Franchini S; Canziani G; Argyropoulos E; Moore WT; Sahu A; Lambris JD
    J Immunol; 2001 Aug; 167(3):1490-9. PubMed ID: 11466369
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Epstein-Barr virus penetration mechanism to T lymphoblastoid cell lines].
    Uno M
    Nihon Rinsho; 1997 Feb; 55(2):404-8. PubMed ID: 9046832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.